Margetuximab was then tested in the single-arm, phase Ib-II P-MGAH22-05 trial that enrolled patients with locally advanced or metastatic HER2-positive GC that progressed after at least one prior treatment including trastuzumab plus chemotherapy.120 Results of this trial showed objective responses in 17 of 92 evaluable patients. This evidence concerns the gene ERBB2 and gastric cancer.